Jump to Navigation

Facebook Connect

User login

NLA Clinical Recommendations Page 1

On June 3, 2015, the anticipated final results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) was published online in the New England Journal of Medicine (NEJM 2015;372:2387-97).

The National Lipid Association (NLA) recently convened an Expert Panel on Statin Safety to examine various aspects of statin therapy and to determine its safety, patient tolerance and effectiveness.

On March 9, 2013, HPS2-THRIVE results were presented at the American College of Cardiology meeting in San Francisco, after which the presenting author concluded “we now know that [niacin’s] adverse side effects outweigh the benefits when used with current treatments.” The National Lipid Association (NLA) is concerned that this very broad study interpretation does not give adequate consideration to two sharply limiting factors in the trial: 1) niacin was clinically irrelevant in the average study subject, and 2) there was substantial subgroup heterogeneity.

Pages



by Dr. Radut.